Introgen Files Advexin For Head And Neck Cancer In U.S., EU
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech says it hopes to follow the Idec/Rituxan model in bringing oncologic gene therapy to the U.S. market.
You may also be interested in...
FDA Refuses To File BLA For Cancer Gene Therapy
Advexin setback compounds dicey financial status of developmental company Introgen.
FDA Refuses To File BLA For Cancer Gene Therapy
Advexin setback compounds dicey financial status of developmental company Introgen.
Introgen Restructures To Ready For Advexin Approval Process
New manufacturing unit could profit from pickup in gene-therapy business.